| MYELODYSPLASTIC SYNDROME
Inqovi vs Tibsovo
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Inqovi vs Tibsovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTibsovo has a higher rate of injection site reactions vs Inqovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tibsovo but not Inqovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inqovi
Tibsovo
At A Glance
Oral
Once daily, Days 1-5 of each 28-day cycle
Nucleoside metabolic inhibitor
Oral
Daily
IDH1 inhibitor
Indications
- MYELODYSPLASTIC SYNDROME
- Refractory anemias
- Refractory anemia with ringed sideroblasts
- Refractory anaemia with excess blasts
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
Dosing
MYELODYSPLASTIC SYNDROME, Refractory anemias, Refractory anemia with ringed sideroblasts, Refractory anaemia with excess blasts, Leukemia, Myelomonocytic, Chronic 1 tablet (35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle, taken on an empty stomach; minimum of 4 cycles until disease progression or unacceptable toxicity.
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, transaminase increased
Serious febrile neutropenia, pneumonia, sepsis
Postmarketing differentiation syndrome, interstitial lung disease, cardiomyopathy
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Pharmacology
Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis; cedazuridine inhibits cytidine deaminase in the gastrointestinal tract and liver to increase systemic exposure of orally administered decitabine.
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inqovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
UnitedHealthcare
Inqovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Inqovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tibsovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InqoviView full Inqovi profile
TibsovoView full Tibsovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.